Lara Sullivan - 31 Mar 2025 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)

Reporting relationship: President ,CEO & CMO, Director
Issuer ticker: PYXS
Reported as of: 31 Mar 2025
Net transaction value: +$899,942
SEC form: 4
Accepted by SEC: 02 Apr 2025, 09:06:50 UTC
Prior SEC filing: 23 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Pamela Connealy, Attorney-in-Fact for Lara Sullivan

Key filing fact

Lara Sullivan filed Form 4 for Pyxis Oncology, Inc. (PYXS) on 02 Apr 2025.

Key facts

This page summarizes Lara Sullivan's Form 4 filing for Pyxis Oncology, Inc. (PYXS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2025, 09:06.

Change

Previous filing in this sequence was filed on 23 Dec 2024.
Current net transaction value: +$899,942.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PYXS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $899,942
Shares: +918,308
Change %
Price: $0.9800
Shares after: 918,308
Date: 31 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 918,308
Exercise price: $0.9800
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31,2025 and the remainder vesting in 36 equal monthly instalments thereafter subject to the reporting person's continued employment through the applicable vesting date.